Publications by authors named "C Thiede"
Article Synopsis
- Researchers found that tandem-duplications of the UBTF gene are linked to severe types of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in young patients, who typically do not respond well to standard treatments.
- The study examined 14 pediatric MDS patients and discovered distinctive bone marrow changes, including hypercellularity, significant dysplasia, and unique features like increased micromegakaryocytes and abnormal erythropoiesis.
- These findings suggest that identifying UBTF mutations through genetic tests can enhance understanding of the disease and help develop better treatment strategies for affected children.
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) is a haemato-inflammatory syndrome genetically defined by somatic mutations in the X-linked UBA1 gene, typically Val/Thr/Leu substitutions at the Met41 hotspot. Clinical manifestations are heterogeneous and refractory to most haemato-rheumatological treatments. To date, no guidelines exist for the management of VEXAS, and scarce is the evidence on methodology and clinical significance of longitudinal UBA1 clonal burden evaluation upon therapy.
View Article and Find Full Text PDFArticle Synopsis
- Since 2017, combining targeted therapies with traditional chemotherapy has led to better outcomes for acute myeloid leukemia (AML) patients.
- A study of 5,359 AML patients over 20 years used data from the HARMONY Alliance to analyze treatment outcomes during four 5-year periods from 1997 to 2016.
- Results show significant improvements in 5-year survival rates and reduced 60-day mortality (from 13.0% to 4.7%), even across different genetic risk groups, indicating that the advancements in treatment have positively affected patient outcomes.
Article Synopsis
- The European LeukemiaNet (ELN) updated its risk classification for acute myeloid leukemia (AML) patients in 2022 (ELN22) and a study evaluated its effectiveness on 1,570 newly diagnosed patients.
- Compared to the previous 2017 classification (ELN17), the new ELN22 showed a similar distribution of risk categories but reclassified 22% of patients, mostly into intermediate or adverse groups, resulting in better prognostic accuracy, particularly for overall survival (OS).
- The study found significant differences in survival rates based on specific gene mutations within the adverse risk group, highlighting the need for tailored treatment approaches based on genetic factors.
Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m with 90 mg/m daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction.
Patients And Methods: Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle.